{"id":"W2956532717","doi":"10.1161/circulationaha.119.042007","title":"Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of British Columbia","funders":"Merck Sharp and Dohme; University of California, San Francisco; Astellas Pharma; Eisai; NxStage; Medical Research Council; Verily Life Sciences; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Pfizer; Innovent Biologics; Janssen Pharmaceuticals; Ablynx; University of Washington; Ironwood Pharmaceuticals, Incorporated; Relypsa; University of Chicago; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; George Institute for Global Health; Kidney Foundation of Canada; Kowa Company; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; GlaxoSmithKline; Amgen; Celgene; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Medicine; Canagliflozin; Diabetes mellitus; Kidney disease; Internal medicine; Hazard ratio; Myocardial infarction; Stroke (engine); Type 2 diabetes; Heart failure; Type 2 Diabetes Mellitus; Endocrinology; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003025301,0.0003122232,0.0009933587,0.0008195732,0.0003216993,0.0006818095,0.0002907945,0.0006016108,0.001953518],"category_scores_gemma":[0.00413699,0.0001948826,0.00129355,0.0006284901,0.0002373147,0.0003037274,0.0005579724,0.000929269,0.0001669456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004471411,"about_ca_system_score_gemma":0.0005848971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002753199,"about_ca_topic_score_gemma":0.003893822,"domain_scores_codex":[0.9986379,0.0005636663,0.0001029898,0.0001797102,0.0003421704,0.0001736424],"domain_scores_gemma":[0.9982054,0.0006688857,0.000488075,0.0001028596,0.0001655181,0.0003691671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04912703,0.00201369,0.8814244,0.0005871633,0.005002409,0.0001031651,0.0001734931,0.000397549,0.0005664665,0.0003054852,0.002506182,0.05779293],"study_design_scores_gemma":[0.005976247,0.0040732,0.9840597,0.0001227676,0.002743127,0.0001852342,0.00007630011,0.0007157479,0.0002115679,0.0003961012,0.001424406,0.0000156258],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817946,0.01302757,0.0002843616,0.0007774514,0.0002071865,0.0001301349,0.0005861059,0.00001463075,0.00317802],"genre_scores_gemma":[0.9962485,0.001739696,0.000334324,0.000317865,0.0002818893,0.0001048294,0.000522706,0.000002319501,0.0004478419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003025301,"threshold_uncertainty_score":0.01599956,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007023360233193048,"score_gpt":0.2075296266487411,"score_spread":0.200506266415548,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}